Epilepsy in inherited metabolic disorders

Neurologist

Volumn 14, Issue 6 SUPPL. 1, 2008, Pages

  Pascual, Juan M ^a   Campistol, Jaume ^b   Gil Nagel, Antonio ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL RUBER INTERNACIONAL   (Spain)

Author keywords

Epilepsy; Metabolic disorders; Neurometabolic disorders

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE; 5 HYDROXYTRYPTOPHAN; ADENINE; ALLOPURINOL; BENZOIC ACID; BIOTIN; CLONAZEPAM; COPPER; DEXTROMETHORPHAN; ETIRACETAM; FOLINIC ACID; GABAPENTIN; HEPTANOIC ACID DERIVATIVE; HISTIDINE; LAMOTRIGINE; LEVODOPA; MAGNESIUM SULFATE; OXCARBAZEPINE; PENICILLAMINE; PHENOBARBITAL; PYRIDOXAMINE PHOSPHATE OXIDASE; PYRIDOXINE; RIBOSE; SULFITE OXIDASE; TOPIRAMATE; URIDINE; VALPROIC ACID;

4 AMINOBUTYRIC ACID METABOLISM; 5 AMINO 4 IMIDAZOLECARBOXAMIDE DEFICIENCY; ACIDURIA; ADENYLOSUCCINATE LYASE DEFICIENCY; ADJUVANT THERAPY; ALPERS DISEASE; AMNIOCENTESIS; ASPARTYLGLYCOSAMINURIA; ATAXIA TELANGIECTASIA; BIOTINIDASE DEFICIENCY; BLOOD ANALYSIS; BONE MARROW TRANSPLANTATION; CARBOHYDRATE DIET; CEREBROTENDINOUS XANTHOMATOSIS; DIET RESTRICTION; DIET THERAPY; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; DISORDERS OF CARBOHYDRATE METABOLISM; DISORDERS OF PEROXISOMAL FUNCTIONS; ENZYME ANALYSIS; ENZYME DEFICIENCY; EPILEPSY; EXCHANGE BLOOD TRANSFUSION; GANGLIOSIDOSIS; GAUCHER DISEASE; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC DISORDER; GLUCOSE TRANSPORTER 1 DEFICIENCY; HUMAN; HYPERGLYCEMIA; INBORN ERROR OF METABOLISM; KETOGENIC DIET; LIPOFUSCINOSIS; LIVER TRANSPLANTATION; MAPLE SYRUP URINE DISEASE; MENKES SYNDROME; METABOLIC DISORDER; METACHROMATIC LEUKODYSTROPHY; NEUROAXONAL DYSTROPHY; NEWBORN PERIOD; NUCLEAR MAGNETIC RESONANCE IMAGING; PERITONEAL DIALYSIS; PHENYLKETONURIA; PORPHYRIA; PRIORITY JOURNAL; PROTEIN RESTRICTION; PYRUVATE CARBOXYLASE DEFICIENCY; PYRUVATE DEHYDROGENASE DEFICIENCY; REVIEW; SANFILIPPO SYNDROME; SIALIDOSIS; ULTRASOUND; WILSON DISEASE;

EPILEPSY; HUMANS; METABOLIC DISEASES;

EID: 57649138073     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.nrl.0000340787.30542.41     Document Type: Review

References (78)

1. Pascual JM. Encephalopathies in neurology and clinical neuroscience. Philadelphia:Mosby; 2007.
2. Pascual JM. Developmental Neurology: a molecular perspective. In: Waxman SG, ed. Molecular neurology. Burlington, MA:Elsevier Academic Press; 2007.
3. Pascual JM. Metabolic diseases of the nervous system. In: Waxman SG, ed. Molecular neurology. Burlington, MA:Elsevier Academic Press; 2007.
4. Chace DH, Kalas TA. A biochemical perspective on the use of tandem mass spectrometry for newborn screening and clinical testing. Clin Biochem. 2005;38:296-309.
5. Christodoulou J, Wilcken B. Perimortem laboratory investigation of genetic metabolic disorders. Semin Neonatol. 2004;9:275-280.
6. Brady RO, Schiffmann R. Enzyme-replacement therapy for metabolic storage disorders. Lancet Neurol. 2004;3:752-756.
7. Aicardi J. Diseases of the nervous system in childhood. Clinics in Developmental Medicine No115/118. London, United Kingdom: Mac Keith Press; 1992.
8. Arzimanoglou A, Guerrini R, Aicardi J, eds. Aicardi's Epilepsy in Children, 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004.
9. Fejerman N. West syndrome [in Spanish]. In: Fernandez-Alvarez E, ed. Pediatric neurology. Buenos Aires, Argentina:Ateneo; 2007.
10. Campistol J. Epileptic syndromes in the first year of life and congenital errors of metabolism [in Spanish]. Rev Neurol. 2000;30(Suppl. 1):S60-S74.
11. Herranz JL, de las Cuevas I. Epileptic signs of metabolic origin [in Spanish]. Rev Neurol. 1999;28(Suppl. 1):S23-S28.
12. Campistol J. Congenital errors of intermediate metabolism in children. Clinical presentation and diagnosis [in Spanish]. Canary Island Pediatrics. 1997;7:99-106.
13. Scriver CR, Beaudet AL, Valle D, Sly WS, eds. The metabolic and molecular bases of inherited diseases, 8th ed. New-York, USA: McGraw-Hill, 2001.
14. Toribe Y. High-dose vitamin B(6) treatment in West syndrome. Brain Dev. 2001;23:654-657.
15. Baxter P. Epidemiology of pyridoxine dependent and pyridoxine responsive seizures in the UK. Arch Dis Child. 1999;81:431-433.
16. Kuo MF, Wang HS. Pyridoxal phosphate-responsive epilepsy with resistance to pyridoxine. Pediatr Neurol. 2002;26:146-147.
17. Mills PB, Beesley CE, Surtees R, et al. The molecular genetics of pyridoxine resistant pyridoxal phosphate sensitive seizures. Amsterdam: Society for the Study of Inborn Errors of Metabolism. Poster presentation: Amsterdam 2004.
18. Clayton PT, Surtees RA, DeVile C, et al. Neonatal epileptic encephalopathy. Lancet. 2003;361:1614.
19. Garcia-Silva MT. New neurometabolic disorders. Clue clinical signs (in Spanish). Rev Neurol. 1999;28:161-168.
20. Torres OA, Miller VS, Buist NM, Hyland K. Folinic acid-responsive neonatal seizures. J Child Neurol. 1999;14:529-532.
21. Campistol J. Congenital errors of metabolism with epileptic seizures during the first years of life [in Spanish]. Rev Neurol. 2002;35(Suppl. 1): S3-S20.
22. Wolf B. Disorders of biotin metabolism. In: Scriver CR, Beaudet AL, Valle D, Sly WS, eds. The metabolic and molecular bases of inherited diseases, 7th ed. New York, USA:McGraw Hill; 1995.
23. Wolf NI, Bast T, Surtees R. Epilepsy in inborn errors of metabolism. Epileptic Disord. 2005;7:67-81.
24. Jaeken J, Van den Berghe G. An infantile autistic syndrome characterised by the presence of succinylpurines in body fluids. Lancet. 1984;2:1058-1061.
25. Van Keuren ML, Hart IM, Kao FT, et al. A somatic cell hybrid with a single human chromosome 22 corrects the defect in the CHO mutant (Ade-I) lacking adenylosuccinase activity. Cytogenet Cell Genet. 1987;44:142-147.
26. Castro M, Perez-Cerda C, Merinero B, et al. Screening for adenylosuccinate lyase deficiency: clinical, biochemical and molecular findings in four patients. Neuropediatrics. 2002;33:186-189.
27. Ciardo F, Salerno C, Curatolo P. Neurologic aspects of adenylosuccinate lyase deficiency. J Child Neurol. 2001;16:301-308.
28. de Koning TJ, Klomp LW. Serine-deficiency syndromes. Curr Opin Neurol. 2004;17:197-204.
29. Takahashi Y, Suzuki Y, Kumazaki K, et al. Epilepsy in peroxisomal diseases. Epilepsia. 1997;38:182-188.
30. Wolf NI, Smeitink JA. Mitochondrial disorders: a proposal for consensus diagnostic criteria in infants and children. Neurology. 2002;59:1402-1405.
31. Molinari F, Raas-Rothschild A, Rio M, et al. Impaired mitochondrial glutamate transport in autosomal recessive neonatal myoclonic epilepsy. Am J Hum Genet. 2005;76:334-339.
32. Pascual JM, Wang D, De Vivo DC. Glut-1 deficiency syndrome. GeneReviews: Medical Genetics Information Resource; Available at: http://www.ncbi.nlm.nih. gov/bookshelf/br.fcgi?book=gene&part=glut1 (accessed September 2008).
33. Pascual JM, Wang D, Lecumberri B, et al. GLUT1 deficiency and other glucose transporter diseases. Eur J Endocrinol. 2004;150:627-633.
34. Menkes JH. Menkes disease and Wilson disease: two sides of the same copper coin. Part I: Menkes disease. Eur J Paediatr Neurol. 1999;3:147-158.
35. Matsuo M, Tasaki R, Kodama H, Hamasaki Y. Screening for Menkes disease using the urine HVA/VMA ratio. J Inherit Metab Dis. 2005;28:89-93.
36. Pascual JM. Disorders of the Krebs cycle and of pyruvate metabolism and transport. In: Rudolph CD, et al., eds. Rudolph's pediatrics, 21st ed. New York: McGraw-Hill, 2003.
37. Lissens W, De Meirleir L, Seneca S, et al. Mutations in the X-linked pyruvate dehydrogenase (E1) alpha subunit gene (PDHA1) in patients with a pyruvate dehydrogenase complex deficiency. Hum Mutat. 2000;15:209-219.
38. Maj MC, Mackay N. Levandovskiy V, et al. Pyruvate dehydrogenase phosphatase deficiency: identification of the first mutation in two brothers and restoration of activity by protein complementation. J Clin Endocrinol Metab. 2005;90:4101-4107.
39. Duran M. Wadman SK. Thiamine-responsive inborn errors of metabolism. J Inherit Metab Dis. 1985;8(Suppl. 1):70-75.
40. Mochel F, DeLonlay P. Touati G, et al. Pyruvate carboxylase deficiency: clinical and biochemical response to anaplerotic diet therapy. Mol Genet Metab. 2005;84:305-312.
41. Robinson BH, MacKay N, Chun K, Ling M. Disorders of pyruvate carboxylase and the pyruvate dehydrogenase complex. J Inherit Metab Dis. 1996;19:452-462.
42. Nyhan WL, Khanna A, Barshop BA, et al. Pyruvate carboxylase deficiency-insights from liver transplantation. Mol! Genet Metab. 2002;77:143-149.
43. Freeze HH, Aebi M. Altered glycan structures: the molecular bass of congenital disorders of glycosylation. Curr Opin Struct Biol. 2005;15:490-498.
44. Jaeken J, Carchon H. Congenital disorders of glycosylation: a booming chapter of pediatrics. Curr Opin Pediatr. 2004;16:434-439.
45. Rapin I, Goldfischer S, Katzman R, et al. The cherry-red spot - myoclonus syndrome. Ann Neurol. 1978;3:234-242.
46. Nalini A, Christopher R. Cerebral glycolipidoses: clinical characteristics of 41 pediatric patients. J Child Neurol. 2004;19:447-452.
47. Wang PJ, Hwu WL, Shen YZ. Epileptic seizures and electroencephalographic evolution in genetic leukodystrophies. J Clin Neurophysiol. 2001;18:25-32.
48. Brett EM, Ellis RB, Haas L, et al. Late onset GM2-gangliosidosis. Clinical, pathological, and biochemical studies on 8 patients. Arch Dis Child. 1973;48:775-785.
49. Rapin I. Myoclonus in neuronal storage and Lafora diseases. Adv Neurol. 1986;43:65-85.
50. Schulte FJ. Clinical course of GM2 gangliosidoses. A correlative attempt. Neuropediatrics. 1984;15(Suppl.):66-70.
51. Santavuori P, Lauronen L, Kirveskari E. et al. Neuronal ceroid lipofuscinoses in childhood. Neurol Sci. 2000;21:535-541.
52. Sinha S, Satishchandra P, Santosh V, et al. Neuronal ceroid lipofuscinosis: a clinicopathological study. Seizure. 2004;13:235-240.
53. Hofman IL, Taschner PE. Late onset juvenile neuronal ceroid- lipofuscinosis with granular osmiophilic deposits (GROD). Am J Med Genet. 1995;57:165-167.
54. Caraballo R, Sologuestua A, Ruggieri VL, et al. Clinical and electroencephalographic aspects of late infantile neuronal ceroid lipofuscinosis [in Spanish]. Rev Neurol. 2005;40:135-140
55. Steinfeld R, Heim P, von Gregory H, et al. Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations. Am J Med Genet. 2002;112:347-354.
56. Binelli S, Canafoglia L, Panzica F, et al. Electroencephalographic features in a series of patients with neuronal ceroid lipofuscinoses. Neurol Sci. 2000;21(Suppl. 1):S83-S87.
57. Ranta S, Lehesjoki AE. Northern epilepsy, a new member of the NCL family. Neurol Sci. 2000;21(Suppl. 1):S43-S47.
58. Mole S, Gardiner M. Molecular genetics of the neuronal ceroid lipofuscinoses. Epilepsia. 1999;40(Suppl. 3):29-32.
59. Dhar S. Bitting RL, Rylova SN, et al. Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic CLN3- and CLN2-deficient neurons. Ann Neurol. 2002;51:448-466.
60. Ruijter GJ, Valstar MJ, van de Kamp JM, et al. Clinical and genetic spectrum of Sanfilippo type C (MPS IIIC) disease in The Netherlands. Mol Genet Metab. 2008;93:104-111.
61. Cali JJ, Hsieh CL, Francke U, Russell DW. Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem. 1991;266:7779-7783.
62. Castelnovo G, Jomir L, Bouly S. Cerebrotendinous xanthomatosis. J Neurol Neurosurg Psychiatry. 2003;74:1335.
63. Waterreus RJ, Koopman BJ, Wolthers BG, Oosterhuis HJ. Cerebrotendinous xanthomatosis (CTX): a clinical survey of the patient population in The Netherlands. Clin Neurol Neurosurg. 1987;89:169-175.
64. Campdelacreu J, Munoz E, Cervera A, et al. Cerebrotendinous xanthomatosis without tendinous xanthomas: presentation of two cases [in Spanish]. Neurologia. 2002;17:647-650
65. Wolthers BG, Walrecht HT, van der Molen JC, et al. Use of determinations of 7-lathosterol (5 alpha-cholest-7-en-3 beta-ol) and other cholesterol precursors in serum in the study and treatment of disturbances of sterol metabolism, particularly cerebrotendinous xanthomatosis. J Lipid Res. 1991;32:603-612.
66. Berginer VM, Salen G, Shefer S. Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N Engl J Med. 1984;311:1649-1652.
67. Winkelman MD, Banker BQ, Victor M. Moser HW. Non-infantile neuronopathic Gaucher's disease: a clinicopathologic study. Neurology. 1983;33:994-1008.
68. Arvio M, Oksanen V, Autio S, et al. Epileptic seizures in aspartylglucosaminuria: a common disorder. Acta Neurol Scand. 1993;87:342-344.
69. Labate A, Barone R, Gambardella A, et al. Startle epilepsy complicating aspartylglucosaminuria. Brain Dev. 2004;26:130-133.
70. Crimlisk HL. The little imitator - porphyria: a neuropsychiatric disorder. J Neurol Neurosurg Psychiatry. 1997;62:319-328.
71. Thadani H, Deacon A, Peters T. Diagnosis and management of porphyria. BMJ. 2000;320:1647-1651.
72. Winkler AS, Peters TJ, Elwes RD. Neuropsychiatric porphyria in patients with refractory epilepsy: report of three cases. J Neurol Neurosurg Psychiatry. 2005;76:380-383.
73. DiMagno EP, Lowe JE, Snodgrass PJ, Jones JD. Ornithine transcarbamylase deficiency - a cause of bizarre behavior in a man. N Engl J Med. 1986;315:744-747.
74. Bogdanovic MD, Kidd D, Briddon A, et al. Late onset heterozygous omithine transcarbamylase deficiency mimicking complex partial status epilepticus. J Neurol Neurosurg Psychiatry. 2000;69:813-815.
75. Oechsner M, Steen C, Sturenburg HJ, Kohlschutter A. Hyperammonaemic encephalopathy after initiation of valproate therapy in unrecognised omithine transcarbamylase deficiency. J Neurol Neurosurg Psychiatry. 1998;64:680-682.
76. Dening TR, Berrios GE, Walshe JM. Wilson's disease and epilepsy. Brain. 1988;111:1139-1155.
77. Brewer GJ, Terry CA, Aisen AM, Hill GM. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch Neurol. 1987;44:490-493.
78. Bostantjopoulou S, Katsarou Z, Michelakaki H, Kazis A. Seizures as a presenting feature of late onset metachromatic leukodystrophy. Acta Neurol Scand. 2000;102:192-195.